Biofilms are structured communities of bacteria encased in a self-produced extracellular polymeric substance (EPS) matrix of polysaccharides, proteins, eDNA, and lipids, adhered to a surface. Formation follows a developmental sequence: reversible attachment → irreversible attachment → microcolony formation → mature biofilm (with fluid channels) → dispersal. Bacteria in biofilms are 10–1000× more tolerant to antibiotics than planktonic cells due to physical diffusion limitation, metabolic dormancy in oxygen-depleted zones, and altered gene expression. Biofilms on medical devices — catheters, implants, prosthetic valves — cause chronic infections that typically cannot be eradicated without device removal.
Compare antibiotic MIC (minimum inhibitory concentration) for planktonic vs. biofilm-embedded bacteria numerically — the orders-of-magnitude difference makes the clinical challenge concrete. Confocal microscopy images of mature biofilms reveal mushroom structures and fluid channels, demonstrating that biofilms are architecturally organized communities, not random aggregates.
You already know that bacteria reproduce through binary fission and that they communicate with one another through quorum sensing — small signaling molecules whose concentration rises with population density. Biofilm formation is what happens when bacteria stop living as free-floating individuals and commit to a communal, surface-attached lifestyle. This transition is not random; it is a coordinated developmental program triggered largely by quorum-sensing signals, and it produces communities with emergent properties that no single bacterium possesses.
The process unfolds in stages. First, planktonic (free-swimming) bacteria encounter a surface — a catheter, a tooth, a rock in a stream — and attach reversibly through weak van der Waals forces and flagella-mediated contact. If conditions are favorable, the attachment becomes irreversible as bacteria produce adhesins and begin secreting extracellular polymeric substance (EPS) — a sticky matrix of polysaccharides, proteins, extracellular DNA (eDNA), and lipids. Think of EPS as the concrete that bacteria pour around themselves: it anchors the community, retains water and nutrients, and creates a physical barrier against threats. As cells divide within this matrix, they form microcolonies that expand into the mature biofilm architecture — mushroom-shaped towers and pillars separated by water-filled channels that function like a primitive circulatory system, delivering nutrients to interior cells and removing waste.
The clinical significance of biofilms lies in their extraordinary antibiotic tolerance. Biofilm-embedded bacteria can be 10 to 1,000 times more resistant to antibiotics than their planktonic counterparts — not because they have acquired resistance genes, but because of the biofilm's physical and physiological properties. The EPS matrix physically impedes antibiotic diffusion, reducing the concentration that reaches interior cells. Deeper within the biofilm, oxygen and nutrient depletion forces bacteria into a slow-growing or dormant metabolic state, and most antibiotics require active growth to kill — β-lactams need cell wall synthesis, fluoroquinolones need DNA replication. These metabolically inactive persister cells survive antibiotic treatment and can later reseed infection. This is why biofilm infections on medical devices (prosthetic joints, heart valves, urinary catheters) are notoriously difficult to treat with antibiotics alone and frequently require surgical device removal.
The final stage of the biofilm lifecycle is dispersal, where cells actively break free from the matrix and return to the planktonic state, colonizing new surfaces. Dispersal can be triggered by nutrient depletion, enzymatic degradation of the EPS matrix, or specific quorum-sensing signals. Understanding this cycle has practical implications: researchers are developing anti-biofilm strategies that target each stage — surface coatings that prevent initial attachment, enzymes like DNase that degrade eDNA in the matrix, quorum-sensing inhibitors that prevent the coordinated gene expression needed for biofilm maturation, and dispersal-promoting agents that force bacteria back into the vulnerable planktonic state where conventional antibiotics can reach them.